Integer's 21% Jump Was the Easy Part-KKR's $127 Offer Still Has a Narrow, Risky Spread

Integer's run already erased most of the obvious upside

The easy upside is likely behind investors. After the rumor hit, Integer shares surged 21%, and a rumored $127 per share KKR offer implies roughly $4.3 billion in value versus a $3.42 billion pre-story market value. Most of the obvious gap has now been traded. What matters next is not whether KKR is interested-it is. The harder question is whether the market is still underestimating how little room remains for deal delay or changed terms.

Anchoring can make an unsettled deal look safer than it is

Once investors anchor to $127 per share, the transaction can start to feel more certain than it actually is. The reported window is still short, with a deal potentially announced as soon as next week. That leaves plenty of room for a sharp repricing in either direction once formal terms-or the absence of them-become clear.

This is an active sale process, not a reluctant target

That risk is easy to understate because Integer is not a hesitant target stumbling into a rumor. The company launched a strategic review in April after receiving interest from potential buyers and said it would consider a sale or merger. This is a live process, with a board already engaging with sellers.

Why Integer appeals to private equity-and why that can still complicate a deal

Because the sale process is active, the key question is less about interest than about fit. Integer has features private equity typically wants: a strategic review already under way launched a strategic review in April and recent operating results that support the story. In the fourth quarter of 2024, sales increased 11% to $449 million, while GAAP operating income rose 31% to $57 million. For a long-horizon buyer, that combination of growth and operating leverage can be hard to ignore.

What makes Integer attractive to a sponsor

This is not a distressed turnaround. It is a specialized medical-device outsourcing business serving a defensive end market. Recent results suggest the company can still grow steadily, which gives a sponsor room to underwrite a take-private deal without leaning too heavily on aggressive assumptions.

Why the same profile can create bargaining friction

The same strengths can also make pricing harder. A business still expected to grow can give sellers a stronger case that the public market is under valuing the next few years of earnings power. That can keep buyers from pressing too hard on price and can make even a thin spread feel riskier than it looks.

The capital structure adds another layer of complexity. Integer issued $875.0 million of convertible notes, upsized from $750.0 million, with associated capped calls carrying a cap price of $189.44 per share. That makes the negotiation more nuanced than a plain equity buyout, because any transaction has to account for the economics and incentives tied to the convertibles.

The spread debate now hinges on confirmation risk, not curiosity

The bull case: recent healthcare buyouts support the premium

Bulls argue this is not just a rumor trade. Recent healthcare buyouts show sponsors still pay up for stable assets in defensive niches, including Avanos Medical at $1.27 billion and Hologic for over $18 billion. If investors read that pattern correctly, they may be less inclined to discount the Integer spread heavily for timing risk.

That view becomes more compelling if a deal arrives quickly. The report said a transaction could be announced as soon as next week, which makes the remaining spread look small relative to the perceived probability of confirmation.

The bear case: the premium is already large and the standalone story is solid

Bears focus on what has already happened to the stock. Integer shares surged 21% on the KKR story, so much of the rumor premium was absorbed before this debate even began.

They also point to management's roadmap. Integer is guiding for 8% to 10% sales growth in 2025 with expanding margins, which gives sellers room to argue the standalone business is already attractive. That is where anchoring gets dangerous: investors can start assuming the full premium will realize because the company is good, not because the deal terms guarantee it. If the final package is delayed or complicated by Integer's convertible senior notes due 2030, the last few dollars of spread can disappear quickly.

What to watch over the next few weeks

At this point, the trade is less about interest and more about timing and structure.

Signals that momentum is holding

• A formal announcement that stays close to the reported roughly $127 per share framework, especially within the near-term window already in the public record.
• Evidence that the board is acting within the process it launched a strategic review in April, rather than reacting to a one-off headline.
• Deal mechanics that look workable around the convertible overhang.

Signals that the spread is too tight

• A material move away from the rumored price level or a timeline that pushes beyond the reported window.
• Signs that financing or note-related mechanics are becoming the bottleneck. Integer's $875.0 million of convertible notes and related capped call transactions could slow or reshape a clean buyout.
• Any treatment of the reported valuation as certainty rather than as a bargaining reference point.

The next few weeks matter because the report said a deal could break as soon as next week. After a sharp rumor-driven run, that is usually when timing risk and structure risk become the real trade.